Search Result

Results for "

α-Syn aggregation inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (12) Amyloid-β (3) COMT (1) Dopamine Receptor (1) DYRK (1) Isotope-Labeled Compounds (1) Monoamine Oxidase (1) Tau Protein (2)
By Research Areas:	Neurological Disease (20)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: α-synuclein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157308

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-139307

MG-2119	Tau Protein	Neurological Disease
MG-2119 is a potent monomeric tau and **α-syn aggregation** inhibitor. MG-2119 is a potential agent for neurological disorders research .

HY-170381

α-syn aggregation inhibitor-1	α-synuclein	Neurological Disease
α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for **α-syn aggregation*. α-syn* aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y .

HY-163739

LETC	α-synuclein	Neurological Disease
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC₅₀ of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .

HY-163519

α-Synuclein inhibitor 13	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

HY-139830

Dyrk1A-IN-1	DYRK	Neurological Disease
Dyrk1A-IN-1 is a triple inhibitor of Dyrk1A kinase activity (IC₅₀ = 119 nM) and the aggregation of tau and α-syn oligomers.

HY-157806

α-Synuclein inhibitor 12	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of *α-Syn* (α-synuclein) aggregation and can be used in the study of neurological diseases .

HY-163830

Pegasus DAD9	Dopamine Receptor	Neurological Disease
Pegasus (DAD9) is a potent dopamine receptor agonist. Pegasus shows antioxidant and anti-inflammatory properties. Pegasus inhibits α-Syn amyloid aggregation. Pegasus has the potential for the research of Parkinson’s disease .

HY-147669

α-Synuclein inhibitor 7	Others	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

HY-147666

α-Synuclein inhibitor 4	α-synuclein	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

HY-147667

α-Synuclein inhibitor 5	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

HY-147668

α-Synuclein inhibitor 6	Others	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

HY-130398

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-170553

ZPD-2	α-synuclein	Neurological Disease
ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .

HY-161328

MAO-B-IN-31	Monoamine Oxidase α-synuclein Tau Protein	Neurological Disease
MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC₅₀ value is 41 nM. MAO-B-IN-31 also inhibits *α-syn* and tau aggregation. MAO-B-IN-31 has neuroprotective activity .

HY-17406S

Tolcapone-d7 Ro 40-7592 d₇	Isotope-Labeled Compounds COMT Amyloid-β	Neurological Disease
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

HY-159945

tau Protein/α-synuclein-IN-2	Amyloid-β α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and *α-syn* inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces *α-syn* oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-149509

α-Synuclein inhibitor 9	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-147644

α-Synuclein inhibitor 3	Others	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-130398

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

Cat. No.	Product Name	Chemical Structure

HY-17406S

Tolcapone-d7
Tolcapone-d₇ is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

α-Syn aggregation inhibitor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products